

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Diagnostics Assessment Programme

Multiple frequency bioimpedance devices (BCM - Body Composition Monitor, BioScan 920-II, BioScan touch i8, InBody S10 and MultiScan 5000) for fluid management in people with chronic kidney disease having dialysis

Provisional stakeholder list

Manufacturer(s) Bodystat Ltd Derwent Healthcare Ltd Fresenius Medical Care Maltron International Ltd
Manufacturer(s) of related technologies (not included in scope) ImpediMed
Professional groups British Association for Paediatric Nephrology Leeds Teaching Hospitals NHS Trust Medicines & Healthcare Products Regulatory Agency The Renal Association The Royal College Of Physicians The Royal College Of Pathologists
Patient/carers groups British Kidney Patient Association Polycystic Kidney Disease Charity
Research groups Kidney Research UK The BISTRO Study Group
Associated guideline groups National Clinical Guidelines Centre
External Assessment Group Aberdeen HTA Group
Others Department of Health Healthcare Improvement Scotland NHS England Welsh Government

Definitions:Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).